Quotient Announces Extension of RapidFACT into Non-Oral Routes of Delivery
Quotient Clinical, part of Quotient Bioresearch (“Quotient”) today announced that three new pharma and biotech clients have selected its RapidFACT service to support the development of optimal drug products for pulmonary, transdermal, and ocular administration. This marks a key extension in the application of RapidFACT across a wide range of dosage forms and delivery routes.
RapidFACT (Rapid Formulation development And Clinical Testing) is underpinned by a Translational Pharmaceutics platform that integrates formulation development, “real-time” GMP product manufacturing, and clinical testing. Compared to conventional development processes, RapidFACT shortens development timelines, lowers costs, and also reduces the consumption of drug substance by up to 90%.
Mark Egerton, Managing Director of Quotient Clinical, said: “We are delighted that RapidFACT has been selected to support the development of these exciting new products. To date, RapidFACT has been deployed on over 30 programs that have focused on oral delivery or intranasal delivery. These new programs further demonstrate the broad utility of RapidFACT and our belief that it can be used to support the development of molecules for any route of delivery.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
